Pharming Group Balances Short-Term Strain With Pipeline Gains

Pharming Group N.V. ((NL:PHARM)) has held its Q1 earnings call. Read on for the main highlights of the call.

Pharming Group’s latest earnings call painted a picture of short‑term pressure but rising confidence in the company’s long‑term trajectory. Management acknowledged an 8% year‑on‑year revenue decline driven by RUCONEST weakness and cash outflows tied to a lease termination, yet highlighted robust Joenja growth, advancing pipeline milestones, and reaffirmed guidance as reasons to expect a return to growth from 2026 onward.

Total Q1 Revenue Under Pressure, Guidance Intact

Pharming reported Q1 2026 revenue of $72.4 million, down 8% versus the prior year as RUCONEST softness offset Joenja’s expansion. Despite the decline, management reaffirmed full‑year 2026 revenue guidance of $405 million to $425 million, implying roughly 8% to 13% growth over 2025 and signaling confidence that current headwinds are temporary.

Joenja Delivers Strong Double‑Digit Growth

Joenja remained the clear bright spot, with revenue climbing 34% year on year to $14.1 million globally as the franchise continued to scale from a small base. U.S. paid patients rose to 127, up 25% versus last year, with seven net new patients added in the quarter and an 85% fill rate underscoring strong adherence and demand.

RUCONEST Franchise Shows Durability Despite Noise

While RUCONEST revenues declined, the underlying franchise still looks resilient as new patient and prescriber additions remained solid. The company added about 50 new patient enrollments and 23 new prescribers in Q1, and management said the vast majority of existing patients remained on therapy nine months after a new oral competitor entered the market.

Regulatory Momentum for Joenja Across Geographies

Joenja’s future growth potential is increasingly tied to regulatory wins, and the call outlined a series of important milestones. The company resubmitted a pediatric supplemental filing for 40 mg and 50 mg doses in April with an expected six‑month review, secured a positive European opinion with a Germany launch planned this year, and is preparing for a Japan launch in August.

Pipeline Catalysts Build Clinical Momentum

Beyond marketed products, Pharming highlighted a growing slate of pipeline events that could expand its rare disease footprint. Two Phase II readouts for leniolisib in higher‑prevalence primary immunodeficiencies are expected later this year, while enrollment for a registrational napazimone study is slated to complete in 2026 with a data readout in 2027, supported by expanded access data indicating clinical and biomarker improvements.

Cost Discipline Supports Positive Operating Cash Flow

The company underscored its focus on profitability and cash discipline, noting positive operating cash flow of $2.0 million in Q1 and a 9% reduction in total operating expenses year over year. For 2026, Pharming expects operating expenses of $330 million to $335 million, aided by a $9 million benefit from a prior 20% reduction in general and administrative headcount while still funding targeted research and development.

Balance Sheet Positioned to Fund Growth Plans

Pharming closed the quarter with $171.8 million in cash and marketable securities, which management believes is sufficient to cover planned pipeline and prelaunch activities alongside future operating cash flows. The company emphasized that it does not rely on any large commercial milestones this year, providing investors with additional comfort around funding for upcoming clinical and commercial investments.

Drivers Behind RUCONEST Revenue Decline

The 15% year‑on‑year drop in RUCONEST revenue was the main drag on total sales, driven largely by technical and strategic factors rather than a collapse in demand. Management cited an expected drawdown in U.S. specialty pharmacy inventories, accounting for around an 8% headwind, and the planned exit from non‑U.S. markets, which contributed roughly a further 3% impact on reported revenue.

Near‑Term RUCONEST Pressure Before Expected Recovery

Investors were warned to brace for additional RUCONEST softness in the second quarter as the full impact of competitive trialing and switching behavior works through multiple reorder cycles. However, management expects conditions to stabilize and inventories to rebuild, supporting a recovery in the franchise and a return to growth from the second half of 2026.

Cash Movement Affected by One‑Time Lease Payment

Despite positive operating cash flow, total cash and marketable securities fell by $9.3 million during the quarter, ending at $171.8 million. The decline was primarily attributed to a $12.3 million payment tied to the early termination of a facility lease, a one‑off item that does not reflect ongoing operating performance.

Operating Profit Pressured by R&D and Prior‑Year Noise

Adjusted operating profit slipped slightly compared with last year as the company absorbed incremental research and development spending while benefiting from lower reported operating expenses. Management cautioned that comparisons are complicated by nonrecurring acquisition costs in the prior period and flagged up to $30 million of potential napazimone development spend within a broader $60 million R&D step‑up for 2026.

Regulatory Path for Pediatric Label Still Has Unknowns

The pediatric regulatory strategy for Joenja remains a work in progress, even as the higher‑dose filing advances. Pharming has opted for a staged approach, with the higher doses already resubmitted and lower‑dose filings targeted for the summer, but acknowledged that timing and acceptance for these lower doses are not yet assured and could influence the pace of pediatric uptake.

Competitive HAE Market Raises Ongoing Risk

The hereditary angioedema market continues to evolve as new oral therapies and prophylactic options increase competition around RUCONEST. While patient retention has so far remained strong, management recognized that these newer entrants pose an ongoing risk to volume and near‑term revenue, reinforcing the need for continued differentiation and patient support.

Joenja’s Growth From a Small Base Limits Near‑Term Impact

Even with its impressive 34% growth, Joenja still represents a relatively small slice of Pharming’s total revenue, making the franchise’s expansion crucial but not yet transformative. Future upside will depend on broadening the patient funnel through pediatric approvals, successful launches in Europe and Japan, and better identification of eligible primary immunodeficiency patients worldwide.

Guidance and Outlook Emphasize H2 2026 Rebound

Management reaffirmed full‑year 2026 revenue guidance of $405 million to $425 million, built on an assumption of low‑single‑digit growth for RUCONEST and a sharper acceleration in Joenja sales versus 2025. The company expects continued pressure in RUCONEST through the second quarter before a second‑half recovery, maintains gross margins around 90%, and plans stepped‑up R&D spending to support leniolisib and napazimone while sustaining positive operating cash generation over time.

Pharming’s earnings call ultimately balanced short‑term caution with longer‑term optimism as investors weigh near‑term RUCONEST pressure against Joenja’s momentum and a pipeline rich in catalysts. For stock watchers, the story hinges on whether Joenja can scale as expected and RUCONEST stabilizes by 2026, which would validate management’s confidence in renewed growth and durable cash generation in the years ahead.